Ocugen (OCGN) said Monday that the European Medicines Agency's Committee for Advanced Therapies had issued a positive opinion for OCU400's classification as advanced therapy medicinal product.
OCU400, Ocugen's gene therapy candidate to treat retinitis pigmentosa, is being evaluated in an ongoing phase 3 trial, the company said.
Ocugen said it intends to file an application for marketing authorization in the EU next year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.